ATE541582T1 - Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen - Google Patents

Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen

Info

Publication number: ATE541582T1
Authority: AT; Austria
Prior art keywords: glp; peptide compositions; stabilized pharmaceutical; peptide; pharmaceutical
Prior art date: 2003-06-03

Application number

AT04735870T

Other languages

English (en)

Inventor

Claus Juul-Mortensen

Dorte Engelund

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-03

Filing date

2004-06-03

Publication date

2012-02-15

2004-06-03 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2004-06-03 Priority claimed from PCT/DK2004/000380 external-priority patent/WO2004105781A2/en

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE541582T1 publication Critical patent/ATE541582T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
239000000203 mixture Substances 0.000 title 1
108010088406 Glucagon-Like Peptides Proteins 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000007935 neutral effect Effects 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Dispersion Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

AT04735870T 2003-06-03 2004-06-03 Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen ATE541582T1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DKPA200300819		2003-06-03
US47627903P	2003-06-05	2003-06-05
DKPA200400075		2004-01-19
US53852504P	2004-01-22	2004-01-22
PCT/DK2004/000380 WO2004105781A2 (en)	2003-06-03	2004-06-03	Stabilized pharmaceutical peptide compositions

Publications (1)

Publication Number	Publication Date
ATE541582T1 true ATE541582T1 (de)	2012-02-15

Family

ID=36645905

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04735870T ATE541582T1 (de)	2003-06-03	2004-06-03	Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen

Country Status (8)

Country	Link
US (2)	US7632806B2 (de)
EP (1)	EP2292254A3 (de)
JP (1)	JP4936884B2 (de)
KR (1)	KR101308912B1 (de)
CN (1)	CN102940879B (de)
AT (1)	ATE541582T1 (de)
BR (1)	BRPI0410972C1 (de)
ES (1)	ES2380437T3 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7635463B2 (en)	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
DE60335608D1 (de) *	2002-02-27	2011-02-17	Pharmain Corp	Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
PL1633391T3 (pl) *	2003-06-03	2012-03-30	Novo Nordisk As	Stabilizowane farmaceutycznie kompozycje peptydowe
WO2005112977A2 (en) *	2004-04-23	2005-12-01	Pharmain, Ltd.	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
KR101529318B1 (ko)	2005-12-19	2015-06-16	파마인 코포레이션	치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
KR101106510B1 (ko)	2006-05-30	2012-01-20	인타르시아 세라퓨틱스 인코포레이티드	투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (de)	2006-08-09	2013-05-22	Intarcia Therapeutics, Inc	Osmotisches Verabreichungssystem mit Kolbenanordnung
KR100746658B1 (ko)	2007-04-23	2007-08-06	성균관대학교산학협력단	소수성 담즙산이 접합된 엑센딘-4 유도체, 이의 제조방법및 이를 포함하는 약학 조성물
WO2008133908A2 (en)	2007-04-23	2008-11-06	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
US7960336B2 (en) *	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
JP2011516541A (ja) *	2008-04-07	2011-05-26	ナショナルインスティテュートオブイミュノロジー	糖尿病および他の慢性疾患の治療に有用な組成物
RU2547990C2 (ru)	2009-09-28	2015-04-10	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
WO2011064316A2 (en)	2009-11-25	2011-06-03	Paolo Botti	Mucosal delivery of peptides
JP5819946B2 (ja) *	2010-05-17	2015-11-24	ベータファーマシューティカルズカンパニーリミテッド	新規のグルカゴン様ペプチド類似体、組成物、および使用方法
US8636711B2 (en) *	2010-06-14	2014-01-28	Legacy Emanuel Hospital & Health Center	Stabilized glucagon solutions and uses therefor
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2526971A1 (de)	2011-05-25	2012-11-28	ArisGen SA	Mukosale Freisetzung von Arzneimitteln
WO2014041375A1 (en) *	2012-09-17	2014-03-20	Imperial Innovations Limited	Peptide analogues of glucagon and glp1
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
MA38724B1 (fr) *	2013-06-28	2017-11-30	Amgen Inc	Formulation liquide stable d'amg 416 (velcalcétide)
EP3080154B1 (de)	2013-12-13	2018-02-07	Sanofi	Duale glp-1/gip-rezeptoragonisten
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TW201613630A (en) *	2014-06-25	2016-04-16	Glaxosmithkline Llc	Pharmaceutical compositions
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru)	2015-06-03	2020-08-26	Интарсия Терапьютикс, Инк.	Системы установки и извлечения имплантата
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
JP7286542B2 (ja)	2017-01-03	2023-06-05	インターシアセラピューティクス，インコーポレイティド	Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
KR102568413B1 (ko)	2017-06-15	2023-08-21	한국전자통신연구원	이온 빔 치료장치
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
CN110551203B (zh) *	2019-09-25	2023-02-10	成都奥达生物科技有限公司	一种艾塞那肽类似物
JP7761567B2 (ja)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤
CN115461044B (zh) *	2020-04-29	2025-06-10	诺和诺德股份有限公司	包含glp-1激动剂和组氨酸的固体组合物
EP4281039A2 (de)	2021-01-25	2023-11-29	Mylan Ireland Limited	Pharmazeutische glp-peptid-zusammensetzungen und verfahren zu ihrer herstellung
IL306122B2 (en) *	2021-05-28	2026-01-01	Guangdong Raynovent Biotech Co Ltd	Preparation and use of polypeptide

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4468346A (en)	1983-10-27	1984-08-28	The United States Of America As Represented By The Secretary Of Agriculture	Monoclonal antibodies to porcine immunoglobulins
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
CA1335765C (en)	1987-05-14	1995-06-06	Robert John Pearce	Whey protein fractions
EP0422124A4 (en)	1988-06-27	1991-10-16	Genex Corporation	Thermal release of recombinant protein into culture media
DE69013471T2 (de)	1989-12-05	1995-03-30	Merck & Co Inc	Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe.
DE4002066A1 (de)	1990-01-25	1991-08-01	Basf Ag	Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
US5272135A (en) *	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv)	1991-05-07	1991-05-07	Tomas Moks	Peptide hormone solution
US5206219A (en)	1991-11-25	1993-04-27	Applied Analytical Industries, Inc.	Oral compositions of proteinaceous medicaments
HK1004520A1 (en)	1992-05-13	1998-11-27	Novartis Ag	Ophthalmic compositions containing a cyclosporin
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
GB9320782D0 (en)	1993-10-08	1993-12-01	Univ Leeds Innovations Ltd	Stabilising of proteins on solution
DE69422637T2 (de)	1993-11-19	2000-06-08	G.D. Searle & Co., Chicago	Transdermale zusammensetzung von n-(n-(5-(4-(aminoiminomethyl)phenyl-1-oxopentyl)-l-alpha-aspartyl)-l-phenylalanin oder deren esterderivaten und ihre pharmazeutischverwendbaren salze
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
WO1995022560A1 (en)	1994-02-22	1995-08-24	The Syntex-Synergen Neuroscience Joint Venture	Pharmaceutical formulations of cntf
US5652216A (en)	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
DK0699687T3 (da)	1994-08-31	2004-04-26	Mitsubishi Pharma Corp	Fremgangsmåde til oprensning af rekombinant humant serumalbumin
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ATE234625T1 (de)	1994-12-23	2003-04-15	Novo Nordisk As	Glp-1 zusammensetzungen mit verlängerter wirkdauer
US6184201B1 (en) *	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) *	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
AU5996996A (en)	1995-06-02	1996-12-18	Novo Nordisk A/S	Al/fe-treatment of a protein solution, followed by membrane concentration
US5631347A (en)	1995-06-07	1997-05-20	Eli Lilly And Company	Reducing gelation of a fatty acid-acylated protein
IL128332A0 (en)	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6384016B1 (en) *	1998-03-13	2002-05-07	Novo Nordisk A/S	Stabilized aqueous peptide solutions
NZ336793A (en)	1997-01-20	2000-08-25	Japan Energy Corp	Method for stabilizing peptides by adding an organic acid and then lyophilizing the peptide mixture
CA2236519C (en) *	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
EP1952802A3 (de)	1997-10-01	2009-06-17	Novadel Pharma Inc.	Oraler, polarer und nicht-polarer Spray bzw. Kapsel
WO1999021889A1 (en)	1997-10-24	1999-05-06	Genentech, Inc.	Purification of molecules
EP1049486A4 (de) *	1997-12-05	2006-01-04	Lilly Co Eli	Glp-1 formulierungen
US6380357B2 (en) *	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
EP1060192A2 (de)	1998-02-27	2000-12-20	Novo Nordisk A/S	Glp-2 derivate mit einem helixgehalt über 25%, die partiell strukturierte mizellenartige aggregate bilden
JP2003522099A (ja) *	1998-02-27	2003-07-22	ノボノルディスクアクティーゼルスカブ	遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
JP2002506792A (ja)	1998-02-27	2002-03-05	ノボノルディスクアクティーゼルスカブ	Ｎ末端修飾ｇｌｐ−１誘導体
WO1999043706A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	Derivatives of glp-1 analogs
EP1061946B1 (de)	1998-02-27	2004-04-28	Novo Nordisk A/S	Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
JP2002524514A (ja) *	1998-09-17	2002-08-06	イーライ・リリー・アンド・カンパニー	タンパク質製剤
CZ295044B6 (cs)	1998-12-07	2005-05-18	Societe De Conseils De Recherches Et D'application	Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
DE69928006T2 (de) *	1998-12-22	2006-07-13	Eli Lilly And Co., Indianapolis	Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
US6902744B1 (en)	1999-01-14	2005-06-07	Amylin Pharmaceuticals, Inc.	Exendin agonist formulations and methods of administration thereof
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
CZ20013018A3 (cs)	1999-03-17	2002-02-13	Novo Nordisk A/S	Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
WO2001000223A2 (en)	1999-06-25	2001-01-04	Minimed Inc.	Multiple agent diabetes therapy
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
CN1409640A (zh)	1999-12-16	2003-04-09	伊莱利利公司	稳定性改善的多肽组合物
US7022674B2 (en) *	1999-12-16	2006-04-04	Eli Lilly And Company	Polypeptide compositions with improved stability
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
US6734162B2 (en)	2000-01-24	2004-05-11	Minimed Inc.	Mixed buffer system for stabilizing polypeptide formulations
EP1396499A3 (de)	2000-01-27	2004-12-29	Eli Lilly And Company	Verfahren zur Lösung von Glucagon-ähnlichen Peptid-1 (GLP-1) Verbindungen
MXPA02007231A (es) *	2000-01-27	2002-12-09	Lilly Co Eli	Proceso para solubilizar los compuestos de peptido 1 similares a glucagon.
US6844321B2 (en)	2000-01-31	2005-01-18	Novo Nordisk A/S	Crystallization of a GLP-1 analogue
WO2001077141A1 (en)	2000-04-06	2001-10-18	Novo Nordisk A/S	Shock heat treatment of polypeptides
JP4716641B2 (ja)	2000-06-16	2011-07-06	イーライリリーアンドカンパニー	グルカゴン様ペプチド−１類似体
CN1340549A (zh) *	2000-08-26	2002-03-20	徐州万邦生化制药有限公司	一种胰高血糖素制备工艺
JP4798833B2 (ja)	2000-10-24	2011-10-19	一般財団法人化学及血清療法研究所	加熱処理工程を含むヒト血清アルブミンの製造方法
AU2002228608A1 (en) *	2000-12-13	2002-06-24	Eli Lilly And Company	Amidated glucagon-like peptide-1
US20020151467A1 (en)	2000-12-21	2002-10-17	Leung Frank K.	Methods and compositions for oral insulin delivery
GB2371227A (en)	2001-01-10	2002-07-24	Grandis Biotech Gmbh	Crystallisation - resistant aqueous growth hormone formulations
DK1360202T3 (da) *	2001-02-16	2008-09-22	Conjuchem Biotechnologies Inc	Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
US6573237B2 (en) *	2001-03-16	2003-06-03	Eli Lilly And Company	Protein formulations
WO2003002136A2 (en) *	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
CN1335182A (zh)	2001-08-08	2002-02-13	华中科技大学	胰岛素口腔喷剂及其制备工艺
AU2002322403A1 (en)	2001-08-23	2003-03-10	Eli Lilly And Company	Glucagon-like peptide-1 analogs
EP1432430A4 (de) *	2001-08-28	2006-05-10	Lilly Co Eli	Vormischungen von glp-1 und basalinsulin
MXPA04003569A (es)	2001-10-19	2004-07-23	Lilly Co Eli	Mezclas bifasicas de glp-1 e insulina.
AU2003215524A1 (en)	2002-03-15	2003-09-29	Natimmune A/S	Pharmaceutical compositions comprising mannose binding lectin
WO2003084563A1 (en)	2002-04-04	2003-10-16	Novo Nordisk A/S	Glp-1 agonist and cardiovascular complications
US7273921B2 (en) *	2002-09-25	2007-09-25	Novo Nordisk A/S	Method for producing acylated peptides
EP1546187B1 (de)	2002-09-25	2008-06-04	Novo Nordisk A/S	Aufreinigungsverfahren, das eine mikrofiltration bei erhöhten temperaturen beinhaltet
WO2004089985A1 (en)	2003-04-11	2004-10-21	Novo Nordisk A/S	Stable pharmaceutical compositions
EP1631308B1 (de)	2003-05-30	2013-07-31	Amylin Pharmaceuticals, LLC	Neue verfahren und zusammensetzungen für die verbesserte transmukosale abgabe von peptiden und proteinen
EP1633390B1 (de)	2003-06-03	2012-01-18	Novo Nordisk A/S	Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
ES2373660T3 (es)	2003-11-13	2012-02-07	Novo Nordisk A/S	Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
US20060287221A1 (en)	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
WO2006025882A2 (en)	2004-08-25	2006-03-09	The Uab Research Foundation	Absorption enhancers for drug administration

2004
- 2004-06-03 KR KR1020127027174A patent/KR101308912B1/ko not_active Expired - Lifetime
- 2004-06-03 EP EP10178212A patent/EP2292254A3/de not_active Withdrawn
- 2004-06-03 AT AT04735870T patent/ATE541582T1/de active
- 2004-06-03 BR BRPI0410972A patent/BRPI0410972C1/pt active IP Right Grant
- 2004-06-03 ES ES04735870T patent/ES2380437T3/es not_active Expired - Lifetime
- 2004-06-03 CN CN201210497503.5A patent/CN102940879B/zh not_active Expired - Lifetime
- 2004-06-03 JP JP2006508132A patent/JP4936884B2/ja not_active Expired - Lifetime
2005
- 2005-11-30 US US11/290,634 patent/US7632806B2/en not_active Expired - Lifetime
2009
- 2009-11-05 US US12/612,888 patent/US8614181B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US8614181B2 (en)	2013-12-24
BRPI0410972B8 (pt)	2018-12-04
US7632806B2 (en)	2009-12-15
JP2008500262A (ja)	2008-01-10
EP2292254A2 (de)	2011-03-09
BRPI0410972B1 (pt)	2018-01-30
JP4936884B2 (ja)	2012-05-23
BRPI0410972C1 (pt)	2021-05-25
CN102940879A (zh)	2013-02-27
EP2292254A3 (de)	2011-12-14
US20060178304A1 (en)	2006-08-10
ES2380437T3 (es)	2012-05-11
KR101308912B1 (ko)	2013-09-23
KR20120130264A (ko)	2012-11-29
BRPI0410972A (pt)	2006-07-04
CN102940879B (zh)	2017-06-06
US20100056451A1 (en)	2010-03-04

Publication	Publication Date	Title
ATE541582T1 (de)	2012-02-15	Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
MXPA05013048A (es)	2006-03-02	Composiciones peptodicas farmaceuticas estabilizadas.
ATE529126T1 (de)	2011-11-15	Stabilisierte pharmazeutische peptid zusammensetzungen
CY1115484T1 (el)	2017-01-04	Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
SE0100568D0 (sv)	2001-02-20	Compounds
CY1113299T1 (el)	2016-04-13	Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
WO2004032909A3 (en)	2004-07-01	Stabilized pharmaceutical composition containing basic excipients
FI20050932A7 (fi)	2005-11-18	Heterobifunktionaaliset polymeeriset biokonjugaatit
TNSN07238A1 (en)	2008-11-21	Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes. pharmaceutical formulations containing the same, and use thereof as medicaments
EA201000643A1 (ru)	2010-08-30	Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
DE60334773D1 (de)	2010-12-16	Formulierungen zur oralen verabreichung von wirkstoffen
WO2006058539A3 (en)	2006-10-26	Growth hormone secretagogue receptor 1a ligands
WO2005037798A3 (en)	2005-06-16	Amide or thiomide derivatives and their use in the treatment of pain
WO2005115470A3 (fr)	2007-03-22	COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
WO2006138608A3 (en)	2007-04-26	Pharmaceutical compositions and use thereof
NO20080552L (no)	2008-03-27	GLP-1 farmasoytiske sammensetninger
DE60215313D1 (de)	2006-11-23	Indolderivate und deren verwendung als gnrh antagonisten
WO2004087880A3 (en)	2005-03-10	Compounds and their use to treat diabetes and related disorders
DE60134735D1 (de)	2008-08-21	Neue neurokinin-antagonisten zum gebrauch als arzneimittel
EA200870223A1 (ru)	2009-02-27	Производные бензоизоиндола для лечения боли
WO2006020207A3 (en)	2007-01-18	Compounds for control of appetite
WO2006113718A3 (en)	2007-12-21	Compositions for the treatment of neoplasms
SE0101692D0 (sv)	2001-05-14	Compounds
WO2007011958A3 (en)	2007-04-12	Intraoral dosage forms of glucagon
BR0112123A (pt)	2003-05-06	Composto